Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

MicuRx Pharma Picks Next-Gen MRSA Antibiotic Candidate

publication date: Aug 19, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

MicuRx Pharmaceuticals, Inc., a privately held company based in the US and Shanghai, China, named its first preclinical development candidate. MicuRX is developing next-generation antibiotics aimed at multi-drug resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). At the same time, the company moved into a new 10,000 square foot laboratory in ZhangJiang HighTech Park in Shanghai. The company had previously presented at the ChinaBio® Investor Forum held in Shanghai last December. More details...

Stock Symbol: (NYSE: PFE)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...